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Abstract: 
Current clinicopathological parameters are useful predictors of breast ductal carcinoma in 
situ behaviour, but they are insufficient to define high risk patients for disease progression 
precisely. Thioredoxin interacting protein (TXNIP) is a key player of oxidative stress. This 
study aims to evaluate the role of TXNIP as a predictor of ductal carcinoma in situ 
progression. Tissue microarrays from 776 pure ductal carcinoma in situ and 239 mixed 
ductal carcinoma in situ and invasive tumors were constructed. All patients were treated 
at a single institution with a long-term follow-up and TXNIP expression was assessed 
using immunohistochemistry. TXNIP expression was investigated in terms of associations 
with clinicopathological and molecular features and patient outcome. Loss/reduced 
cytoplasmic expression of TXNIP was associated with features of aggressiveness including 
high nuclear grade (p=1.6x10-5), presence of comedo necrosis (p=0.001) and oestrogen 
receptor negative (ER-)/HER2- ductal carcinoma in situ (p=4.6x10-5). Univariate analysis 
showed an inverse association between TXNIP expression and outcome in terms of 
shorter local recurrence free survival (p=0.009). Multivariable analyses showed that 
independent predictors of ductal carcinoma in situ recurrence were low TXNIP expression 
(p=0.005, HR=0.51 and 95%CI: 0.32-0.81), larger ductal carcinoma in situ size and high 
nuclear grade. TXNIP functions as a tumor suppressor gene with loss of its expression 
associated with ductal carcinoma in situ recurrence. TXNIP can be used as a potentially 
useful marker in prognostic stratification of ductal carcinoma in situ for management 
decisions.  
  
INTRODUCTION: 
The main aim of ductal carcinoma in situ management is to prevent local recurrence 
particularly invasive recurrence (1). Despite a low mortality risk, ductal carcinoma in situ 
is often treated with mastectomy or breast conservative surgery with frequent re-excisions 
compared to invasive disease (2). Mastectomy results in very few recurrences but is often 
considered as over-treatment for screen-detected precursor lesions. Conversely, breast 
conservative surgery alone increases the risk of recurrence which may be considered as 
under-treatment in a proportion of high risk ductal carcinoma in situ (3). Radiotherapy 
can reduce the recurrence rate by approximately 50% but has significant side-effects and 
its application should therefore be rationalized. Accurate risk stratification of ductal 
carcinoma in situ means not only predicting recurrence but also which patients are likely 
to progress to invasive disease.  
Ductal carcinoma in situ is observed in more than half of invasive breast cancer (4) and in 
the majority of these cases, they share morphology, immunoprofile and genetic features 
suggesting that the invasive component arises from the associated ductal carcinoma in 
situ (5-7). However, there remains a lack of objective predictive markers of ductal 
carcinoma in situ behavior; not only of recurrence but also development of invasive 
disease that could aid in treatment decisions.  
Clinicopathological characteristics are used as prognostic factors in guiding treatment 
decisions (3) but they are insufficient to reflect the molecular and clinical heterogeneity. 
Assessment of molecular markers can be used as surrogates of ductal carcinoma in situ 
biology and behavior and have the potential to predict patient outcome (8). It is known 
that cancer cells continuously experience oxidative stress, resulting from heightened 
reactive oxygen species generation (9). Enhanced oxidative stress has been implicated in 
the initiation and progression of cancer, promoting cell survival and drug resistance in 
some cases (10). However, unresolved high levels of oxidative stress beyond the capacity 
of the cancer cell to manage causes critical damage to cellular DNA, proteins and lipids 
ultimately leading to cell death (11). A negative regulator of the major anti-oxidant 
thioredoxin (TRX), thioredoxin interacting protein (TXNIP) has potent growth suppressive, 
metastasis inhibitory and pro-apoptotic functions (12). Loss of TXNIP expression was 
reported to be associated with the development of some solid tumors (12). In the breast, 
high expression of TXNIP was reported in normal breast tissues (13) and showed reduced 
immunointensity in invasive tumors (14). Ectopic expression of TXNIP in the breast cancer 
cell line MCF-7 drives cells to undergo senescence, accompanied by increased reactive 
oxygen species release. In a study of 98 locally advanced invasive breast cancer treated 
with anthracycline-based chemotherapy, Woolston and colleagues (15) have 
demonstrated that TXNIP is an independent predictor of outcome. 
We hypothesized that oxidative stress could play a role in breast cancer progression and 
that TXNIP might be a potential prognostic marker in ductal carcinoma in situ. In this 
study, TXNIP expression was assessed in a large (n=1015) and well-characterized cohort 
of ductal carcinoma in situ from a single institution with long term follow-up. In addition, 
the prognostic significance of TXNIP gene copy number and gene expression was assessed 
in a large cohort of invasive breast cancer (n=1980) as a molecular surrogate of ductal 
carcinoma in situ. 
 
PATIENTS AND METHODS 
Study Cohort 
This retrospective study was conducted on a consecutive series of 1059 primary pure 
ductal carcinoma in situ cases diagnosed, and treated in a uniform manner, between 1990 
to 2012 at the Nottingham City Hospital, Nottingham, UK. Exclusion of referral, miscoded 
and recurrent cases resulted in 776 pure primary ductal carcinoma in situ with available 
formalin-fixed paraffin embedded tumor blocks for tissue microarray construction. A series 
of 239 cases diagnosed as synchronous ductal carcinoma in situ and invasive tumors 
(mixed ductal carcinoma in situ and invasive breast cancer) was also collected as a 
validation set. Patients’ demographic information, histopathological parameters, 
management, radiotherapy and patient outcome data were collated. No patients were 
treated with hormonal therapy.  Local recurrence free survival was calculated based on 
the time (in months) from the date of primary surgical treatment to the time of ipsilateral 
local recurrence. The median follow-up period, in pure ductal carcinoma in situ cohort, was 
118 months (range 2 to 240 months), during which 90 patients (14%) developed local 
ipsilateral recurrence including invasive (60/90; 67%) or ductal carcinoma in situ (30/90; 
33%). Recurrence following breast conserving surgery and mastectomy occurred in 84 
and 6 cases respectively. 
Patients who developed contralateral disease following ductal carcinoma in situ diagnosis 
were censored at the time of diagnosis of the contralateral cancer. 
Tissue Microarray and Immunohistochemistry 
Tissue microarrays were prepared from representative ductal carcinoma in situ lesions of 
the pure cases and from ductal carcinoma in situ and invasive tumors from the mixed 
cases. The tissue microarray was constructed using 3D Histech® Grand Master®, whereby 
cores of 1 mm and 0.6 mm were taken from ductal carcinoma in situ and invasive tumor 
samples respectively. In addition, a set of whole tissue sections from 10 cases containing 
ductal carcinoma in situ and invasive tumors were assessed to evaluate heterogeneity and 
the pattern of TXNIP expression in normal and malignant breast lesions. 
Validation of TXNIP antibody (Abcam; clone EPR14774) specificity was performed using 
Western blotting on whole cell lysates of MCF-7, SKBr3 and MDA-MB-231 human breast 
cancer cell lines (obtained from the American Type Culture Collection; Rockville, MD, USA). 
TXNIP antibody was used at 1:3000 dilution which showed a single specific band at the 
predicted size of 44 kDa (Figure 1A). 
Expression of TXNIP protein in ductal carcinoma in situ was assessed by 
immunohistochemistry using the Novocastra Novolink polymer detection system (Leica, 
Newcastle, UK). 4 m tissue microarray and full-face sections were stained with mouse 
monoclonal TXNIP antibody (1:3000) for 30 min. 3,30-Diaminobenzidine 
tetrahydrochloride (Novolink DAB substrate buffer) was used as a chromogenic substance. 
Sections were counterstained with hematoxylin. Positive staining controls (human tonsil 
and kidney tissue) were included while a negative control was achieved by omitting the 
application of the primary antibody. Expression of estrogen receptor (ER) in ductal 
carcinoma in situ was carried out using ER clone SP1, Ventana Benchmark® ULTRA system 
(Tucson, Arizona, USA), as per the recommended protocol (Supplementary material 1). 
A cut-off of ≥1% for ER staining positivity was used (16). HER2 status was assessed using 
immunohistochemistry staining (1:400, DAKO, no antigen retrieval) with HercepTest 
scoring method as previously published (16, 17) (Supplementary material 1). In 
equivocal cases (HER2 immunohistochemistry score 2+), HER2 gene amplification was 
determined by chromogenic in situ hybridization using ZytoDot 2CSPEC ERBB2/CEN 17 
Probe Kit (Supplementary material 2) (17, 18) 
Cytoplasmic TXNIP staining was assessed using the semi-quantitative H-score taking into 
consideration the intensity of staining and the percentage of stained tumor cells within 
each tissue core (19). All cases were scored blinded to clinicopathological and outcome 
data. Cases with multiple cores (n=210) were scored and the average was used as the 
final score.  
This work obtained ethics approval by the North West – Greater Manchester Central 
Research Ethics Committee under the title; Nottingham Health Science Biobank (NHSB), 
reference number 15/NW/0685. 
 
Analysis of TXNIP in invasive breast cancer: 
To confirm the prognostic and clinical significance of TXNIP in invasive breast cancer, as a 
molecular surrogate of ductal carcinoma in situ in the breast, TXNIP gene copy number 
and normalized gene expression (mRNA) data were analyzed using the Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) dataset that comprises 
1980 tumors with long term follow-up (20).  
 
Statistical analysis 
Statistical analyses were performed using SPSS v23 (Chicago, IL, USA) for Windows. X-
tile software program (Yale University, version 3.6.1) was utilized to define the optimal 
cut-off point for TXNIP expression (H-score 120) with corrected p value and relative risk 
against local recurrence free survival (21, 22). Association between TXNIP expression and 
clinicopathological parameters using categorized data was evaluated using Chi-squared 
test. Survival rates were determined using the Kaplan–Meier method and compared by 
the log-rank test. Multivariate analysis using Cox proportional hazard regression model 
determined the influence of TXNIP expression, when adjusted to other variables, on local 
recurrence free survival. All tests were 2-tailed and a p value of less than 0.05 was 
considered as statistically significant. 
RESULTS 
Analysis of TXNIP mRNA levels in invasive breast cancer revealed significant association 
between reduced levels/loss of expression and high histological grade (p=0.004), large 
tumor size (p=0.003), advanced stage tumors (p=0.01), and with ER-negative and HER2-
positive phenotype (p=0.003 and p=0.011 respectively) and luminal B and basal intrinsic 
subtypes according to the PAM50 classification (p=6.7x10-27) (Supplementary Table 1). 
Loss of copy number and reduced TXNIP mRNA expression were associated with worse 
outcome in terms of shorter breast cancer specific survival (p=0.003 and p=0.002 
respectively) (Supplementary Figure 1). Reduced TXNIP mRNA expression was also 
associated with loss of copy number (p=0.049). These findings confirmed the tumor 
suppressor function of TXNP in breast cancer and its potential prognostic value and 
supported investigating its role in ductal carcinoma in situ.  
Frequency and localization pattern of TXNIP in ductal carcinoma in situ 
Assessment of whole tissue sections revealed cytoplasmic expression of TXNIP in a 
homogenous distribution pattern with occasional nuclear staining in normal luminal and 
myoepithelial cells. The homogenous pattern of expression confirmed the validity of using 
tissue microarray technology to assess its expression. Variable staining intensities and 
localization was detected in the different morphological components, with occasional 
strong nuclear staining in normal breast epithelial cells, strong to moderate cytoplasmic 
staining in ductal carcinoma in situ (with occasional membrane accentuation) and mild to 
negative cytoplasmic staining in invasive tumors (with no nuclear staining). TXNIP positive 
pure ductal carcinoma in situ tumor cells exhibited distinct cytoplasmic staining with 
occasional peripheral/perimembrane accentuation and infrequent nuclear staining in some 
low-grade tumors (Figure 1). After exclusion of uninformative cores (i.e., loss and/or 
folding of cores), a total of 636 pure ductal carcinoma in situ and 231 tumors with mixed 
ductal carcinoma in situ and invasive components were included in the analysis. TXNIP 
expression showed a unimodal distribution with a median H-score of 185 (range 0-300) in 
the pure ductal carcinoma in situ.  
In mixed ductal carcinoma in situ and matched invasive cancer, both components were 
consistently positive in 27 (12%) cases and negative in 65 (28%) cases. High ductal 
carcinoma in situ /Low invasive breast cancer expression for TXNIP was present in 134 
(58%) cases however, there were 5 (2%) cases in which invasive breast cancer was 
positive/high expressing and ductal carcinoma in situ low expressing for TXNIP. When pure 
ductal carcinoma in situ was compared to ductal carcinoma in situ mixed with invasive 
breast cancer, a statistically significant difference was detected, with the TXNIP 
cytoplasmic mean H-score being higher in pure ductal carcinoma in situ tumors 
(𝑋
¯
±SD=185± 76, 𝑋
¯
±SD= 112 ± 88 respectively; t-test= 15.8 and p<0.0001). In the 
mixed cases, a significant difference was also observed whereby the TXNIP cytoplasmic 
mean H-score was higher in the ductal carcinoma in situ component when compared with 
the adjacent invasive component (𝑋
¯
±SD= 112 ± 88, 𝑋
¯
±SD= 83± 78 respectively; 
Z=16.6 and p<0.0001) (Supplementary Figure 2). Similar results were observed when 
TXNIP was analyzed as a categorical variable (Chi-squared p<0.001 for pure vs mixed 
ductal carcinoma in situ and p<0.001 for ductal carcinoma in situ vs adjacent invasive 
components). No nuclear expression was seen in tumor cells of the cases mixed with 
invasion. 
Association of TXNIP with clinicopathological parameters in pure ductal 
carcinoma in situ 
High/positive TXNIP cytoplasmic expression was significantly associated with good 
prognostic factors in ductal carcinoma in situ including low nuclear grade (p=1.6x10-5), 
absence of comedo type necrosis (p=0.001), positive ER status (p=2x10-6), negative HER2 
status (p=0.007) and with the luminal (ER+/HER2-) phenotype (p=4.6x10-5). (Table 1).  
Association with Patient Outcome of pure ductal carcinoma in situ 
In univariate analysis, patients with positive TXNIP expression had a significantly longer 
local recurrence free survival (log rank (LR)=7.99, 95%CI:0.34-0.83 and p=0.009, Figure 
2A). When the analysis was restricted to patients who underwent breast conservative 
surgery, to avoid the impact of surgical management on outcome prediction, TXNIP 
expression retained its significant association with improved outcome (LR=6.67, 
95%CI:0.39-0.88 and p=0.04, Figure 2B). No significant association was observed 
between TXNIP expression and the type of local recurrence. 
Positive TXNIP expression was associated with improved outcome in the group of patients 
treated with breast conservative surgery without post-operative radiotherapy (94/220) 
(p=0.02) but not in those who were offered radiotherapy (21/93) (p=0.5) (Figure 2C 
and 2D).  
In ductal carcinoma in situ cases treated with breast conservative surgery without post-
operative radiotherapy, loss/reduced TXNIP expression was observed in 126 cases and 
those showed approximately 40% recurrence rate (51/126), such patients could be 
candidates for radiotherapy to improve local recurrence free survival. low TXNIP 
expression was also associated with recurrence of 17% (12/72) of cases in the group of 
patients treated with breast conservative surgeryand postoperative radiotherapy, which 
points out the importance of TXNIP as a predictor marker. Overall proportion of 
recurrences after breast conservative surgery that showed low TXNIP expression were 
75% (63/84). 
 
When molecular classes were considered, high TXNIP was associated with improved 
outcome in the luminal (ER+/HER2-) class (p=0.04, Figure 2E). 
 
Multivariate Cox regression model including ductal carcinoma in situ size, nuclear grade 
and presence of comedo necrosis showed that high TXNIP expression was an independent 
predictor of good outcome in pure ductal carcinoma in situ (p=0.005, HR 0.51, 95% CI 
0.32-0.81) (Table 2). 
 
DISCUSSION 
The treatment of ductal carcinoma in situ remains a challenge as the clinicopathologic 
features of the disease do not reliably stratify patients into distinct risk groups to guide 
treatment decision (23). For this reason, some studies have attempted to risk stratify 
ductal carcinoma in situ based on genetic and molecular factors including Oncotype Dx® 
ductal carcinoma in situ score (24-28). Although ductal carcinoma in situ score minimised 
the proportion of patients undergoing radiotherapy, the assay seems expensive and not 
cost-effective (29). In fact, none of the investigated parameters has been translated to 
clinical practice. Therefore, there is a pressing need to identify cost-effective and robust 
biomarker(s) to predict outcome for ductal carcinoma in situ patients. 
The role of TXNIP expression was investigated in different tissues (30-34) including locally 
advanced invasive breast cancer (15) and we observed that loss of TXNIP expression was 
associated with features of increasing aggressiveness. It is likely that the effect of TXNIP 
on cell growth and proliferation are cell-context dependent and might be circumvented via 
activation of alternate mitogenic pathways (9), nevertheless the data is consistent with 
TXNIP being a tumor suppressor (30). TXNIP expression in cancer might be downregulated 
through epigenetic, transcriptional, post-transcriptional, or translational mechanisms (35).  
To date, there is no well-established robust publically available database for ductal 
carcinoma in situ mRNA or copy number aberrations. To confirm the prognostic 
significance of TXNIP mRNA in breast cancer and assess the role of copy number alteration 
on its expression and function, we have used the METABRIC cohort. This analysis showed 
that loss of copy number is one of the mechanisms for downregulation of TXNIP, which is 
associated with aggressive behavior and poor outcome. Utilizing a large annotated series 
of ductal carcinoma in situ treated at a single institution, we have demonstrated that TXNIP 
downregulation is associated with increased aggressiveness and poor outcome in terms of 
shorter local recurrence free survival. We also found downregulation of TXNIP expression 
in invasive disease compared to the co-existing ductal carcinoma in situ. These results 
support our hypothesis that TXNIP is a tumor suppressor in breast cancer.  
Our results demonstrate that loss of expression of TXNIP in ductal carcinoma in situ is not 
only associated with parameters characteristic of poor prognosis but is also an independent 
predictor of recurrence. These results are in line with TXNIP functioning as a tumor 
suppressor that is reported to be commonly silenced by genetic or epigenetic mechanisms 
in cancer cells (11, 36).  
In this study, a significant negative association between the expression of TXNIP and local 
recurrence in ductal carcinoma in situ was identified. A previous study indicated that TXNIP 
stabilizes cyclin-dependent kinase inhibitor p27, which plays a pivotal role in inhibiting cell 
proliferation and apoptosis resulting in G1
 
arrest and inhibition of cell cycle (37). This 
observation may explain our finding that high TXNIP expression was associated with low 
grade, low proliferating ER positive and HER2 negative ductal carcinoma in situ and with 
longer local recurrence free survival. Independent of its interaction with TRX, TXNIP has 
the ability to inhibit cell cycle progression by indirectly inhibiting mammalian target of 
rapamycin (mTOR), a regulator of cell growth and metabolism (38). Therefore, in addition 
to inducing a metabolic shift important to tumor biology, downregulation of TXNIP is likely 
to promote cell survival, growth, invasion, and metastasis. TXNIP can also reduce tumor 
invasion and angiogenesis through inhibition of TRX and can directly have an impact on 
cell survival by promoting a pro-apoptotic environment (39, 40). The exact mechanisms 
by which TXNIP exerts its tumor suppressive functions in ductal carcinoma in situ cells are 
not yet fully clear. Future studies of the mechanisms by which TXNIP is expressed and 
functions in ductal carcinoma in situ will improve our understanding of the progression to 
invasive disease.  
In this study, a significant correlation between TXNIP expression and ER+/HER2- status 
was identified. This finding is consistent with previous reports indicating that TXNIP may 
interrupt HER2 mediated oncogenic effect (36). To our knowledge, few studies have 
reported an explicit impact of HER2 signaling on TXNIP expression. It might suggest that 
there is a direct link between ERBB2 and TXNIP or could be explained by the glucose 
theory. It is well known that cancer cells experience energetic stress and glucose 
deprivation especially in HER2 positive cancer cells (37). Glucose induces TXNIP 
expression, and reactive oxygen species triggers the dissociation of TXNIP from TRX, 
leading to increased TXNIP availability (41). Therefore, TXNIP may be induced by 
hyperglycemia regulated TRX- reactive oxygen species activity in the HER2 signaling 
pathway. Information regarding this mechanism will require further investigation in the 
future. 
The current study demonstrated differential expression of TXNIP between pure ductal 
carcinoma in situ and ductal carcinoma in situ associated with invasive disease, which may 
have potential application for predicting invasive disease in ductal carcinoma in situ 
diagnosed on preoperative biopsy samples, after further validation. In addition, the ability 
of TXNIP to inhibit the major reactive oxygen species scavenger TRX, further regulate cell 
cycle progression and metastasis and promote apoptosis, clearly identifies TXNIP as an 
important therapeutic target.  
In conclusion, the difficulty in implementing predictive markers for ductal carcinoma in 
situ remains the availability of large cohorts with consistent treatment for validation, and 
our study is an exception. We report that TXNIP is an independent prognostic factor and 
a potential tumor suppressor in breast cancer. Overexpression of TXNIP in ductal 
carcinoma in situ is therefore a good prognostic factor that can potentially improve ductal 
carcinoma in situ risk stratification for management purpose. Further functional studies 
are recommended to extensively validate the role of TXNIP as a predictor of progression 
to invasive disease. 
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Figure 1: Characterization of TXNIP expression in ductal carcinoma in situ: (A) Western blot analysis 
of the anti-TXNIP antibody confirmed a single specific band at 44 kDa in a variety of cell lines, image 
for MCF7 shown, (B) TXNIP cytoplasmic expression in normal breast tissue showing expression in 
the epithelium and a few scattered myoepithelial cells. Occasional membrane and/or nuclear staining 
is also seen. TXNIP immunohistochemistry expression in ductal carcinoma in situ showing variable 
intensities from negative (C), weak (D), moderate (E) and strong (F) staining (x20 magnification). 
(G) is full face section of a ductal carcinoma in situ case mixed with invasive carcinoma and show 
moderate TXNIP expression in ductal carcinoma in situ but reduced/negative expression in the 
adjacent invasive carcinoma component.  
Figure 2: Kaplan Meier curves show that high expression of TXNIP is associated with (A) longer 
local recurrence free survival in the whole series (p=0.009), (B) improved survival in patients treated 
with breast conserving surgery (p=0.04), (C) improved outcome in non-radiotherapy treated 
patients (p=0.02), (D) Local recurrence free survival in radiotherapy treated patients (p=0.50), (E). 
TXNIP is also associated with Local recurrence free survival when ductal carcinoma in situ stratified 
into luminal ER+/HER2- (p=0.040).  
  
Table 1: Correlation between TXNIP expression and the clinicopathologic variables of 
pure ductal carcinoma in situ cases.  
 
Parameter 
TXNIP Expression 
 
n (%) 
High (n=225) 
n (%) 
Low (n=411) 
n (%) 
χ2 
(p value) 
Age, years* 
   Less than 40 
   Between 40 and 60 
   More than 60 
 
23 (3.6) 
371 (58.3) 
242 (38.1) 
 
10 (5) 
131 (58) 
84 (37) 
 
13 (4) 
240 (58) 
158 (38) 
 
0.71 
(0.702) 
Presentation 
   Screening 
   Symptomatic 
 
302 (47.5) 
334 (52.5) 
 
113 (50) 
112 (50) 
 
221 (54) 
190 (46) 
 
0.73 
(0.391) 
Ductal carcinoma in situ Size (mm) 
   Less than 16 
   Between 16 and 40 
   More than 40 
 
218 (34.3) 
246 (38.7) 
167 (26.3) 
 
84 (37) 
80 (36) 
57 (25) 
 
134 (33) 
166 (40) 
110 (27) 
 
4.73 
(0.098) 
Nuclear Grade 
   Low 
   Intermediate 
   High 
 
87 (13.7) 
162 (25.5) 
387 (62.8) 
 
50 (22) 
61 (27) 
114 (51) 
 
37 (9) 
101 (25) 
273 (66) 
 
24.88 
(1.6x10-5) 
Ductal carcinoma in situ histologic type 
   Single 
   Mixture** 
 
312 (49.1) 
324 (50.9) 
 
113 (50) 
112 (50) 
 
199 (48) 
212 (52) 
 
0.189 
(0.664) 
Comedo necrosis 
   Yes 
   No 
 
403 (63.4) 
233 (36.6) 
 
122 (54) 
103 (46) 
 
281 (68) 
130 (32) 
 
12.45 
(0.001) 
Coexistent LCIS 
   Yes 
   No 
 
58 (9.1) 
578 (90.9) 
 
21 (9) 
204 (91) 
 
37 (9) 
374 (91) 
 
0.02 
(0.890) 
 Coexistent Paget’s 
   Yes 
   No 
 
31 (9) 
304 (51) 
 
7 (6) 
102 (94) 
 
24 (11) 
202 (89) 
 
2.42 
(0.463) 
Management 
   Mastectomy 
   Breast Conserving Surgery 
 
323 (50.7) 
313 (49.3) 
 
110 (49) 
115 (51) 
 
213 (52) 
198 (48) 
 
3.56 
(0.207) 
Radiotherapy*** 
   Yes 
   No 
 
96 (15.1) 
540 (84.9) 
 
35 (16) 
190 (84) 
 
61 (15) 
350 (85) 
 
0.06 
(0.516) 
Estrogen Receptor Status 
   Positive 
   Negative 
 
412 (75) 
137 (25) 
 
150 (87) 
22 (13) 
 
262 (69) 
115 (31) 
 
22.46 
(2x10-6) 
HER2 Status**** 
   Negative 
   Positive 
 
471 (80) 
120 (20) 
 
178 (85) 
31 (15) 
 
293 (76) 
89 (23) 
 
12.15 
(0.007) 
Molecular Classification 
   ER+/HER2- 
   ER-/HER2+ 
   ER+/HER2+ 
   ER-/HER2- 
 
342 (53.8) 
61 (9.6) 
43 (6.8) 
66 (10.4) 
 
139 (79) 
12 (7) 
14 (8) 
10 (6) 
 
203 (60) 
49 (14) 
29 (9) 
56 (17) 
 
24.02 
(4.6x10-5) 
 
p value in bold: significant, TXNIP: Thioredoxin Interacting Protein 
n: Number, LCIS: Lobular Carcinoma in situ,  
*Age: categorized according to the Van Nuys Prognostic Index (VNPI), **Histologic type is 
a mixture of more than one morphologic type, *** 93 cases who were treated with 
radiotherapy belong to breast conserving surgery group, the remaining 3 cases were 
treated with mastectomy ****HER2 final status is achieved using combination of IHC and 
chromogenic in situ hybridization (CISH).
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Table 2: Multivariate Cox proportional hazards for predictors of local recurrence in pure 
ductal carcinoma in situ patients.  
 
Variable HR 95% CI p-value 
Ductal carcinoma in situ size 0.60 0.46-0.89 <0.001 
Ductal carcinoma in situ Grade 1.83 1.24-2.70 <0.001 
Comedo necrosis 0.97 0.54-1.73 0.911 
TXNIP expression 0.51 0.32-0.81 <0.001 
HR: Hazard Ratio, CI: Confidence Interval, TXNIP: Thioredoxin Interacting Protein 
Significant p values are represented in bold 
